Trial reportBlood advances2023
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Registry-linked trialAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03013998 (A Master Protocol for Biomarker-Based Treatment of AML), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.Annals of hematology · 2025Pooled it
- A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.Journal of hematology & oncology · 2023Trial
- Protein neddylation as a therapeutic target: challenges and opportunities.The Journal of clinical investigation · 2026Review
- Neddylation: from regulatory mechanisms to clinical implications in cancer.Journal of advanced research · 2026Review
- UBA3 reduction sensitizes cancer cells to NAE inhibitors.Life science alliance · 2026Article
- Molecular and Clinical Insights intoInternational journal of molecular sciences · 2025Review
- NEDDylation Regulates CD8+ T-cell Metabolism and Antitumor Immunity.Cancer immunology research · 2025Article
- MLN4924 Suppresses Acute Myeloid Leukemia Progression by LINC01128-Driven Epigenetic Reactivation of TRIM58.Drug design, development and therapy · 2025Article
- Dual role of targeting NAE1 in nasopharyngeal carcinoma: Antitumor effects yet inducing radiotherapy resistance.Heliyon · 2024Article
- A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.Haematologica · 2024Article
- Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615).European journal of cancer (Oxford, England : 1990) · 2024Article
- Unmet Horizons: Assessing the Challenges in the Treatment ofJournal of clinical medicine · 2024Review
- New insights into SUMOylation and NEDDylation in fibrosis.Frontiers in pharmacology · 2024Review
- Review
- TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.Mediterranean journal of hematology and infectious diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Antoine N SalibaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.ORCID 0000-0001-5134-7336
Scott H KaufmannDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4900-7145
Eytan M SteinLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Prapti A PatelDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
Maria R BaerUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Wendy StockDepartment of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL.
Michael DeiningerDivision of Hematology and Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT.ORCID 0000-0002-2987-1331
William BlumWinship Cancer Institute of Emory University, Atlanta, GA.
Gary J SchillerDavid Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.
Rebecca L OlinUniversity of California, San Francisco, San Francisco, CA.
Mark R LitzowDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.ORCID 0000-0002-9816-6302
Tara L LinDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.
Brian J BallDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Michael M BoyiadzisUniversity of Pittsburgh Hillman Cancer Center, Pittsburgh, PA.
Elie TraerKnight Cancer Institute, Oregon Health & Science University, Portland, OR.ORCID 0000-0001-8844-2345
Olatoyosi OdenikeDepartment of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL.
Martha L ArellanoWinship Cancer Institute of Emory University, Atlanta, GA.
Alison WalkerThe Ohio State University, Columbus, OH.
Vu H DuongUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.ORCID 0000-0003-0278-7727
Tibor KovacsovicsDivision of Hematology and Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT.
Robert H CollinsDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
Abigail B ShobenThe Ohio State University, Columbus, OH.
Nyla A HeeremaThe Ohio State University, Columbus, OH.
Matthew C FosterUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.ORCID 0000-0002-6652-3838
Kevin L PetersonDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Paula A SchneiderDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Molly MartyczThe Ohio State University, Columbus, OH.
Theophilus J GanaBiopharmatech Consulting, Inc., Leesburg, VA.
Leonard RosenbergLeukemia and Lymphoma Society, White Plains, NY.
Sonja MarcusLeukemia and Lymphoma Society, White Plains, NY.
Ashley O YocumLeukemia and Lymphoma Society, White Plains, NY.
Timothy ChenThe Ohio State University, Columbus, OH.
Mona StefanosThe Ohio State University, Columbus, OH.
Alice S MimsThe Ohio State University, Columbus, OH.ORCID 0000-0002-8971-2199
Uma BorateThe Ohio State University, Columbus, OH.
Amy BurdLeukemia and Lymphoma Society, White Plains, NY.
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University, Portland, OR.ORCID 0000-0001-8331-8206
Ross L LevineLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
John C ByrdDepartment of Medicine, University of Cincinnati, Cincinnati, OH.
James M ForanDivision of Hematology-Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MOncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6MBAK Autoactivation in Hematological MalignanciesR01CA225996 · NCI · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H · 2020 to 2024
$1.8MNCI NIH HHS K12 CA001727NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA225996
Abstract
PubMed holds no abstract for this paper.
Indexed as
AzacitidineLeukemia, Myeloid, AcuteAgedCyclopentanesHumansPyrimidinesTumor Suppressor Protein p53AzacitidineCyclopentanespevonedistatPyrimidinesTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT03013998ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.